Form 4: REGENXBIO Director Reports Stock Transactions

REGENXBIO Inc. Director Kenneth T. Mills reported transactions involving common stock and stock options on May 29, 2026.

Summary

• Kenneth T. Mills, a Director at REGENXBIO Inc., reported the acquisition of 9,807 shares of common stock on May 29, 2026, with a reported value of $0.00. This acquisition is related to a time-based restricted stock unit (RSU) award, with 100% of the shares vesting on May 29, 2027, contingent on continuous service.
• Additionally, Mr. Mills acquired 46,600 stock options (right to buy) on the same date, with an exercise price of $7.01 per share. These options are set to vest on May 29, 2027, also subject to continuous service.
• Following these transactions, Mr. Mills beneficially owns 495,925 shares of common stock directly and 46,600 shares indirectly through the stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine equity awards and option grants to a director, which are standard compensation practices and do not inherently signal significant positive or negative developments for the company.

Positives

• Director Kenneth T. Mills acquired additional equity in the company through RSU awards and stock options, indicating continued commitment and alignment with shareholder interests.
• The RSU award and stock options are subject to vesting conditions tied to continuous service, which incentivizes long-term employee retention and performance.

Negatives

• The filing does not provide details on the market value of the acquired shares or options at the time of the transaction, only the reported $0.00 value for the RSU shares and the exercise price for the options.

Risks

• The vesting of RSUs and stock options is contingent on the continuous service of the reporting person, implying a risk of forfeiture if service is not maintained.
• The stock options have an exercise price of $7.01, meaning they will only be profitable if the market price of REGENXBIO Inc. common stock exceeds this level.

Future Outlook

The future outlook for the reported transactions is tied to the vesting schedule of the RSUs and stock options, which are set for May 29, 2027. The profitability of the stock options depends on the future market performance of REGENXBIO Inc. common stock exceeding the $7.01 exercise price.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported on Form 4, are common in the biotechnology sector as companies utilize equity-based compensation to attract and retain talent. The vesting schedules are typical for incentivizing long-term commitment in a high-growth, research-intensive industry.

Stakeholder Impact

• Shareholders: The transactions reflect continued alignment of director compensation with long-term company performance, potentially benefiting shareholders through motivated leadership.
• Employees: The vesting conditions for RSUs and options highlight the company's strategy to retain key personnel, which can contribute to stable operations and innovation.
• Management: The reporting person, as a director, is subject to the terms of the equity awards, reinforcing their commitment to the company's success.

Next Steps

• Continuous service by Kenneth T. Mills to REGENXBIO Inc. until May 29, 2027, for the vesting of RSUs and stock options.
• Potential exercise of stock options by Kenneth T. Mills on or after May 29, 2027, if deemed financially advantageous.

Key Dates

Keywords

REGENXBIO Inc., RGNX, Form 4, SEC Filing, Stock Options, Restricted Stock Units, Insider Trading, Beneficial Ownership, Director Transactions, Equity Awards